A Phase 3 Study of MRTX849 vs Docetaxel in Advanced NSCLC

• Research type

  Research Study

• Full title

  A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

• IRAS ID

  1003655

• Contact name

  Bill Paxton

• Contact email

  849-012@mirati.com

• Sponsor organisation

  Mirati Therapeutics, Inc.

• Eudract number

  2020-003645-11

• Clinicaltrials.gov Identifier

  NCT04685135

• Research summary

  This is an open label randomised phase III study of an investigational (experimental) medication called MRTX849 given alone (single agent) versus single agent chemotherapy docetaxel (also known as TAXOTERE®).
  The primary purpose of this study is to compare the effectiveness of MRTX849 versus docetaxel in participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with a specific change in tumour genes (KRAS G12C mutation) who have previously had progression on or after chemotherapy and immunotherapy. Up to approximately 452 participants are expected to participate in this study.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  21/LO/0398

• Date of REC Opinion

  2 Jul 2021

• REC opinion

  Further Information Favourable Opinion